Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients
作者： Michael R. Goldberg , Thomas E. Bradstreet , Edward J. McWilliams , Wesley K. Tanaka , Stephanie Lipert
关键词: Endocrinology 、 Aldosterone 、 Angiotensin II 、 Enalapril 、 Angiotensin II receptor antagonist 、 Renin–angiotensin system 、 Internal medicine 、 Medicine 、 Losartan 、 Angiotensin-converting enzyme 、 Plasma renin activity 、 Pharmacology
摘要: We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood pressure, 95 to 110 mm Hg). Qualifying (n = 51) were allocated placebo, 25 or 100 mg losartan, 20 enalapril. Blood plasma drug concentrations, and mediators measured 4 inpatient days: end placebo run-in, after first dose, 2 6 weeks treatment. Plasma concentrations similar last doses losartan. At weeks, enalapril showed comparable antihypertensive activity. Four hours dosing, compared run-in day, increased renin activity 1.7-fold Ang 2.5-fold, whereas 2.8-fold decreased 77%. Both drugs aldosterone concentration. For increases greater at than weeks. Effects dose related. After changes by 36 hours. These results indicate that long-term feedback produces modest do not appear affect response antagonist.
sci-hub.st 参考文章(27)
P. K. S. Siegl, Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. Journal of Hypertension. ,vol. 11, ,(1993)
R. R. Wexler, A. L. Johnson, D. J. Carini, P. C. Wong, P. B. W. M. Timmermans, A. T. Chiu, W. A. Price, J. V. Duncia, Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. Journal of Pharmacology and Experimental Therapeutics. ,vol. 255, pp. 211- 217 ,(1990)
Milo Gibaldi, Biopharmaceutics and clinical pharmacokinetics ,(1977)
M. Ohtawa, F. Takayama, K. Saitoh, T. Yoshinaga, M. Nakashima, Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. British Journal of Clinical Pharmacology. ,vol. 35, pp. 290- 297 ,(1993) , 10.1111/J.1365-2125.1993.TB05696.X
Y Christen, B Waeber, J Nussberger, M Porchet, R M Borland, R J Lee, K Maggon, L Shum, P B Timmermans, H R Brunner, Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation. ,vol. 83, pp. 1333- 1342 ,(1991) , 10.1161/01.CIR.83.4.1333
E S Kisch, R G Dluhy, G H Williams, Enhanced aldosterone response to angiotensin II in human hypertension. Circulation Research. ,vol. 38, pp. 502- 505 ,(1976) , 10.1161/01.RES.38.6.502
V. Mooser, J. Nussberger, L. Juillerat, M. Burnier, B. Waeber, J. Bidiville, N. Pauly, H. R. Brunner, Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. Journal of Cardiovascular Pharmacology. ,vol. 15, pp. 276- 282 ,(1990) , 10.1097/00005344-199002000-00015
John R. Cockcroft, David G. Sciberras, Michael R. Goldberg, James M. Ritter, Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. Journal of Cardiovascular Pharmacology. ,vol. 22, pp. 579- 584 ,(1993) , 10.1097/00005344-199310000-00011
T J Moore, G H Williams, R G Dluhy, S Z Bavli, T Himathongkam, M Greenfield, Altered Renin-Angiotensin-Aldosterone Relationships in Normal Renin Essential Hypertension Circulation Research. ,vol. 41, pp. 167- 171 ,(1977) , 10.1161/01.RES.41.2.167
J. K. Doig, R. J. MacFadyen, C. S. Sweet, K. R. Lees, J. L. Reid, Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. Journal of Cardiovascular Pharmacology. ,vol. 21, pp. 732- 738 ,(1993) , 10.1097/00005344-199305000-00007